Compound heterozygous splicing and missense variants in MYO7A in a Chinese patient with Usher syndrome
Frontiers in Medicine · 24.07.2026 · 13
DOI: 10.3389/fmed.2026.1836745 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 24.07.2026. Verfasst von Juyi Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tongji Medical College, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, Hubei, China. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Wuhan, horizontal research project of the Central Hospital of Wuhan, Central Guiding Local Science and Technology Development Special Project.
Abstract (Originalsprache)
Objective
The objectives of the present study were to identify the genetic variations in a Chinese patient with Usher syndrome and to determine the pathogenicity of the identified variations.
Methods
Whole-exome sequencing was performed for the proband. Alphafold3 and PyMOL software were used to determine the impact of a variation on three-dimensional protein structure. A Minigene Splicing Assay was performed to investigate the impact of a variant on MYO7A splicing.
Results
Two compound heterozygous missense and splicing variations of MYO7A (NM_000260:c.487G > A:p.G163R, rs1472566324 and c.2187 + 2_2187 + 8del, rs1416744060) were identified in the proband. After glycine (G, WT) is replaced by arginine (R, rs1472566324), arginine forms additional hydrogen bonds with the surrounding amino acids. In the Minigene Splicing Assay, abnormal splicing bodies (associated with an Exon18 jump) were observed in the mutant plasmids (rs1416744060). This abnormal splicing event caused a deletion of 31 aa inside the protein, generating a truncated protein of 2,184 aa.
Conclusion
Compound heterozygous missense and splicing variants of MYO7A (rs1472566324 and rs1416744060) were the likely pathogenic variants of a patient with Usher syndrome type 1B.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Tongji Medical College, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Department of Nephrology, Tongji Medical College, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Department of Pain, Tongji Medical College, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Department of Medical Genetics, School of Basic Medical Science, Wuhan University, Wuhan, Hubei, China.
- Department of Ophthalmology, Tongji Medical College, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Department of Teaching Office, Tongji Medical College, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Förderung
- Natural Science Foundation of Wuhan
- horizontal research project of the Central Hospital of Wuhan
- Central Guiding Local Science and Technology Development Special Project
Zitieren
APA
Li, J., Mao, H., Li, L., Wang, X., Yang, G., Yu, J., Deng, A., Hu, J., Wu, D., Zhan, P., & Li, Y. (2026). Compound heterozygous splicing and missense variants in MYO7A in a Chinese patient with Usher syndrome. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1836745
Vancouver
Li J, Mao H, Li L, Wang X, Yang G, Yu J, et al. Compound heterozygous splicing and missense variants in MYO7A in a Chinese patient with Usher syndrome. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1836745
BibTeX
@article{Li2026,
author = {Li, Juyi and Mao, Huihui and Li, Lu and Wang, Xiufang and Yang, Guohua and Yu, Jiguo and Deng, Aiping and Hu, Jifa and Wu, Dan and Zhan, Peiyan and Li, Yingbo},
title = {Compound heterozygous splicing and missense variants in MYO7A in a Chinese patient with Usher syndrome},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1836745}
}
EUVIMED